Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Pliant Therapeutics (PLRX) Operating Expenses (2019 - 2025)

Pliant Therapeutics (PLRX) has disclosed Operating Expenses for 7 consecutive years, with $23.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Operating Expenses fell 55.78% to $23.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $156.4 million, a 31.52% decrease, with the full-year FY2025 number at $156.4 million, down 31.52% from a year prior.
  • Operating Expenses was $23.6 million for Q4 2025 at Pliant Therapeutics, down from $28.3 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $62.0 million in Q3 2024 to a low of $23.6 million in Q4 2025.
  • A 5-year average of $40.6 million and a median of $41.4 million in 2022 define the central range for Operating Expenses.
  • Peak YoY movement for Operating Expenses: surged 48.0% in 2022, then tumbled 55.78% in 2025.
  • Pliant Therapeutics' Operating Expenses stood at $26.6 million in 2021, then surged by 48.0% to $39.4 million in 2022, then grew by 19.49% to $47.0 million in 2023, then grew by 13.36% to $53.3 million in 2024, then crashed by 55.78% to $23.6 million in 2025.
  • Per Business Quant, the three most recent readings for PLRX's Operating Expenses are $23.6 million (Q4 2025), $28.3 million (Q3 2025), and $45.6 million (Q2 2025).